文献速递类风湿关节炎

强化管理对中度活动性已确诊类风湿关节炎的临床有效性:TITRATE试验

The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial.
PubMed 文献 · Semin Arthritis Rheum · 2020-07-30

TITRATE试验为12个月多中心个体随机试验,纳入335例已确诊、中度活动且正在使用csDMARDs的RA患者,比较标准 care 与每月强化管理(含临床评估、药物滴定和心理社会支持)。强化管理组12个月DAS28-ESR缓解率显著高于标准 care 组(32% vs 18%,p=0.004),并显著改善疲劳,未增加不良事件。

要点

  • 强化管理使已确诊中度活动RA的12个月DAS28-ESR缓解率从18%提高至32%。
  • 强化管理还显著提高替代缓解标准达标率和低疾病活动度比例(48% vs 32%)。
  • 强化管理显著减轻疲劳,且未增加严重不良事件或其他不良事件。

核心结论

  • 由经过专门培训的医疗专业人员提供的包含心理社会支持的强化管理,对中度活动性已确诊类风湿关节炎有效。
  • 更多患者达到缓解,疲劳改善更明显,且未增加危害。

研究设计与样本

  • 12个月多中心个体随机试验,比较标准 care 与每月强化管理预约。
  • 强化管理由经过专门培训的医疗专业人员实施,包括每月临床评估、药物滴定和心理社会支持。
  • 335例患者被随机分配(强化管理168例;标准 care 167例),303例(90%)提供12个月结局数据。

主要发现

  • 强化管理组12个月DAS28-ESR缓解率为32%,标准 care 组为18%(p=0.004)。
  • 强化管理组DAS28-ESR低疾病活动度比例为48%,标准 care 组为32%(p=0.005)。
  • 强化管理显著减轻疲劳(平均差异-18;95% CI:-24,-11,p<0.001)。
  • 严重不良事件强化管理组15例 vs 标准 care 组11例,其他不良事件114例 vs 151例,无证据表明强化管理显著增加不良事件。

关键数值与推荐

  • 主要结局为12个月缓解,采用基于ESR的28关节疾病活动度评分(DAS28-ESR)评估。
  • 强化管理还显著提高了采用一系列替代缓解标准的缓解率。

临床怎么用

  • 对已确诊、中度活动且正在使用csDMARDs的RA患者,可考虑每月强化管理(含临床评估、药物滴定和心理社会支持)以提高缓解率并改善疲劳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Many trials have shown that intensive management is effective in patients with early active rheumatoid arthritis (RA). But its benefits are unproven for the large number of RA patients seen in routine care who have established, moderately active RA and are already taking conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). The TITRATE trial studied whether these patients also benefit from intensive management and, in particular, achieve more remissions. METHODS: A 12-month multicentre individually randomised trial compared standard care with monthly intensive management appointments which was delivered by specially trained healthcare professionals and incorporated monthly clinical assessments, medication titration and psychosocial support. The primary outcome was 12-month remission assessed using the Disease Activity Score for 28 joints using ESR (DAS28-ESR). Secondary outcomes included fatigue, disability, harms and healthcare costs. Intention-to-treat multivariable logistic- and linear regression analyses compared treatment arms with multiple imputation used for missing data. RESULTS: 459 patients were screened and 335 were randomised (168 intensive management; 167 standard care); 303 (90%) patients provided 12-month outcomes. Intensive management increased DAS28-ESR 12-month remissions compared to standard care (32% vs 18%, p = 0.004). Intensive management also significantly increased remissions using a range of alternative remission criteria and increased patients with DAS28-ESR low disease activity scores. (48% vs 32%, p = 0.005). In addition it substantially reduced fatigue (mean difference -18; 95% CI: -24, -11, p<0.001). There was no evidence that serious adverse events (intensive management =15 vs standard care =11) or other adverse events (114 vs 151) significantly increase with intensive management. INTERPRETATION: The trial shows that intensive management incorporating psychosocial support delivered by specially trained healthcare professions is effective in moderately active established RA. More patients achieve remissions, there were greater improvements in fatigue, and there were no more harms.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Scott D, Ibrahim F, Hill H, et al. The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial. Semin Arthritis Rheum. 2020. PMID: 32931984. doi:10.1016/j.semarthrit.2020.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。